ArticleMicrosystems & nanoengineering2026
Vertical-flow tearable paper-tape rolls for scalable multiplexed point-of-care nucleic acid testing.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular point-of-care: technological evolution, clinical applications, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Paper substrates, with their inherent capillary-driven forces, eliminate the need for external power sources typically required by microfluidic biochips. However, conventional lateral flow (LF) systems face limitations, including non-specific adsorption, uneven molecular distribution, and restricted flexibility for multiplexed detection. In this work, we developed a novel vertical-flow paper-tape (VFPT) integrated device. By engineering a gradient pore-size paper substrate and replacing pre-patterned channels with gravity-driven flow, this innovation achieves size-selective molecular transport while doubling the effective transport distance. Its roll-to-roll fabrication process enables scalable, low-cost production with customizable detection capabilities. As a proof of concept, the VFPT device demonstrated detection limits of 200 copies/mL for HIV and HBV and 600 copies/mL for HCV, comparable to PCR and superior to traditional paper-based systems. Validation with 203 blinded clinical plasma samples revealed sensitivity and specificity exceeding 90.9%. This innovative platform offers a user-friendly, accurate, and cost-effective solution for clinical diagnostics and resource-limited settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.